Actually I'm glad you mentioned the revenue numbers.
If you take the customer receipts for CY2020, you end up with a total of $13.9m
If you add the other income, then you get to $15.7m (it's not quite clear what the other income is, it may be exercised options? + other bits and pieces )
So the commentary about 16-17m etc is quite wrong. (You can confirm these numbers by reading their own reports)
Given their cash burn rate, even excluding the financing costs, they are likely halfway into their Akuna financing already, provided they haven't acquired more 15-20% loans from the shareholders.
They've also lost their recurring revenue from China, which would indicate negative growth in the VSN area?
My memory might be failing me, but didn't they announce they would have hundreds of thousands in ongoing consulting and support fees from the clients they obtained during covid?
- Forums
- ASX - By Stock
- NET
- Ann: Half Year Report and Appendix 4D
Ann: Half Year Report and Appendix 4D, page-22
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NET (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $11.63M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
NET (ASX) Chart |
Day chart unavailable
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
SPONSORED BY The Market Online